InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (11 ops.)
Discover the detailed record of transactions filed by Wu Xiaobin, Chief Operating Officer. Insider active across 2 companies, notably BeiGene, Ltd.. Cumulatively, 18 filings have been logged. Total volume traded: €4.6m. The latest transaction was disclosed on 22 June 2022 — Attribution. Regulator: SEC (Form 4). All data is free.
Declarations18 total
49,000 shares
ShareXHKG
HKEX:DA20260409E00113·
340,000 shares
ShareXHKG
HKEX:DA20260401E00052·
Ideal exit: 22 Dec 2026 (T+270)
0187,876 shares0
Ordinary Shares
SEC:0001651308-22-000111:0·
€76,507578 shares@ €132.36550.0002% mcap1.7% of flow
American Depositary Shares
SEC:0001651308-22-000090:0·
€452,8883,410 shares@ €132.81180.0014% mcap9.9% of flow
American Depositary Shares
SEC:0001651308-22-000079:0·
€122,750800 shares@ €153.43770.0004% mcap2.7% of flow
American Depositary Shares
SEC:0001651308-22-000067:0·
0
RMB Shares
SEC:0001651308-21-000262·
0
RMB Shares
SEC:0001651308-21-000262:0·
€88,976300 shares@ €296.58678.8% of flow
American Depositary Shares
SEC:0001651308-21-000224·
€88,976300 shares@ €296.58670.0003% mcap1.9% of flow
American Depositary Shares
SEC:0001651308-21-000224:0·
€108,744400 shares@ €271.860810.7% of flow
American Depositary Shares
SEC:0001651308-21-000149·
€108,744400 shares@ €271.86080.0003% mcap2.4% of flow
American Depositary Shares
SEC:0001651308-21-000149:0·
078,000 shares0
Ordinary Shares
SEC:0001651308-21-000128·
078,000 shares0
Ordinary Shares
SEC:0001651308-21-000128:0·
€816,2672,825 shares@ €288.94480.5% of flow
American Depositary Shares
SEC:0001651308-21-000110·
€816,2672,825 shares@ €288.9440.0025% mcap17.8% of flow
American Depositary Shares
SEC:0001651308-21-000110:0·
6,715 shares
American Depositary Shares
SEC:0001651308-21-000080·
€2m6,715 shares@ €284.38130.0060% mcap41.6% of flow
American Depositary Shares
SEC:0001651308-21-000080:0·
18 of 18 declarations
About Wu Xiaobin
Wu Xiaobin is the Chief Operating Officer of BeiGene, Ltd. He oversees the company's operations in the biopharmaceutical sector.
